Erbitux Ups PFS in Metastatic Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 1
Volume 16
Issue 1

ImClone Systems and Bristol-Myers Squibb have announced that a phase III study of cetuximab (Erbitux) plus FOLFIRI (an irinotecan-based chemotherapy regimen) met the primary endpoint of increasing median duration of progression-free survival (PFS) over FOLFIRI alone in patients with previously untreated metastatic colorectal cancer.

NEW YORK—ImClone Systems and Bristol-Myers Squibb have announced that a phase III study of cetuximab (Erbitux) plus FOLFIRI (an irinotecan-based chemotherapy regimen) met the primary endpoint of increasing median duration of progression-free survival (PFS) over FOLFIRI alone in patients with previously untreated metastatic colorectal cancer. More than 1,000 patients were recruited from around the world to participate in the study, known as the CRYSTAL study, the companies said. Results have been submitted for presentation at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago in June.

"Despite advancements, metastatic disease remains difficult to treat. The study demonstrates the potential benefit of adding Erbitux to first-line treatment of metastatic colorectal cancer," said Eric Rowinksy, MD, CMO of ImClone.

Cetuximab is a monoclonal antibody designed to inhibit the function of EGFR. Erbitux in combination with radiotherapy is approved for locally or regionally advanced squamous cell carcinoma of the head and neck. As a single agent, it is indicated for patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Related Content